Akebia Therapeutics Reports Q2 2026 Financial Results

What Happened
Akebia Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2026 via a press release on August 5, 2026. The press release reporting the company’s quarterly results and recent business highlights was furnished as Exhibit 99.1 to the Form 8-K (Item 2.02). The filing is signed by John P. Butler, President and Chief Executive Officer.

Key Details

• Filing date: August 5, 2026; quarter covered: ended June 30, 2026.
• The company furnished its press release as Exhibit 99.1 to the Form 8-K.
• Item reported: 2.02 (Results of Operations and Financial Condition); exhibits listed under 9.01 include the press release (Exhibit 99.1).
• Form 8-K signed by CEO John P. Butler.

Why It Matters
This 8-K is the company’s official SEC disclosure that its quarterly earnings, revenue and other financial results for Q2 2026 are available; investors should review the Exhibit 99.1 press release for the specific revenue, earnings, cash position and business updates. Quarterly results and business highlights can materially affect valuation and trading sentiment, so read the press release and any accompanying materials (earnings release, investor presentation, or call) for the detailed numbers and management commentary.